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Abstract: Background. Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disorder worldwide, comprises a 
spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. NASH is associated with an 
increased risk of hepatocellular carcinoma (HCC) and cardiometabolic disease. Insulin resistance (IR) is the underlying pathogenic 
mechanism for NAFLD, the presence of which in turn, is a strong predictor for the development of metabolic disorders. Hence, therapy 
of NAFLD with insulin-sensitizing drugs (ISDs) should ideally improve the key hepatic histological changes (steatosis, inflammation and 
fibrosis), but should also reduce cardiometabolic and cancer risk. 
Objectives. In this review, the rationale for the use of ISDs and the evidence for their efficacy are detailed. In particular, the mechanism 
of action, potential for use, limitations and untoward effects of metformin and thiazolidinediones are systematically reviewed. Further, 
we discuss novel ISDs that may have potential clinical utility in NAFLD. 
Results and Conclusion. Despite the theoretical prediction that ISDs might have beneficial effects on disease outcomes, evidence that 
ISDs are able to alter the natural history of NAFLD are presently not available. The exploration of novel strategies exploiting “non-
conventional” ISDs is encouraged. 
Keywords: Adiponectin; dipeptidyl peptidase-IV inhibitors; estrogens; glucagon-like peptide-1; hepatocellular carcinoma; insulin sensitizing 
drugs; metformin; nonalcoholic fatty liver disease; rimonabant; thiazolidinediones; ursodeoxycholic acid. 
BACKGROUND 
 Nonalcoholic Fatty Liver Disease (NAFLD), a spectrum of 
disorders ranging from simple steatosis to nonalcoholic steatohepa-
titis (NASH) with/without cirrhosis, and hepatocellular carcinoma 
(HCC) [1] is the most common chronic liver disease, with a preva-
lence of 25% in the general population of Western Countries [2].  
 The prevalence of NAFLD is increased in subjects with type 2 
diabetes mellitus (35%-90%), obesity (10%-80%), hypertension 
(30%-56%) and dyslipidemia (26%-58%)[3]. Age, gender and eth-
nicity also influence NAFLD prevalence; NAFLD is more common 
in older subjects and in males, but prevalence rates could be an 
underestimate given the often suboptimal diagnostic methods used 
[4]. The prevalence of hepatic steatosis in the Dallas Heart Study 
followed a clear-cut gradient with Hispanics being more affected 
than whites, and African Americans ranking as the ethnic group 
with the least prevalence of NAFLD [5]. A more recent analysis 
confirmed that ethnicity represents a major determinant for the risk 
of developing NASH for a given level of insulin resistance (IR) [6]. 
Primary NAFLD is typically associated with IR and the Metabolic 
Syndrome (MetS) [7]. Diagnosis requires the exclusion of other 
causes of liver disease such as viral infection, autoimmune diseases, 
alcohol abuse, endocrine and genetic disorders [8].  
 NAFLD is an early predictor of metabolic disorders, even in 
non-diabetic and non-obese subjects [9]. It is associated with an 
increased risk for all cause mortality, end-stage liver disease, car-
diovascular disease, HCC and some hepatic and extrahepatic can-
cers [10,12-20]. Despite the relative accuracy of non-invasive 
methods for predicting advanced fibrosis [10], liver biopsy remains 
the gold-standard for the grading and staging of NAFLD [2,11].  
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In animal studies, a direct progression from steatosis to NASH has 
been observed, leading to speculation that “multiple hits” are in-
volved in the pathophysiology of a single disease spanning a wide 
spectrum . However, more recent views support the concept that 
simple steatosis and NASH appear as two distinct entities and pro-
gression from pure fatty liver to NASH appears to be so rare as to 
warrant publication [84]  
 The ideal treatment for NAFLD should improve the key his-
tological changes of NASH (steatosis, inflammation and fibrosis) 
and reduce morbidity and mortality from cardiometabolic diseases 
and cancer, particularly HCC [14,21]. Diabetic patients are known 
to have a high prevalence of NAFLD/NASH [22] and are recog-
nized to be at higher risk for HCC [23-30 ]. Additionally, in diabet-
ics, 50% of cases of HCC develop in non-cirrhotic livers [31-33] 
and overall, only 46% of patients with NAFLD and HCC have been 
shown to have cirrhosis [34]. The putative mechanisms underlying 
the development of HCC in NAFLD relate to IR and to the associ-
ated inflammatory cascade [35]. Hence, Insulin-sensitizing drugs 
(ISDs) might be effective in preventing NAFLD-associated HCC, 
but data to confirm or refute this assertion are still awaited. 
 ISDs therapy of NASH has been extensively investigated. 
However, most trials are relatively small, proof-of-concept studies. 
The largest body of data in humans is available for two classes of 
ISDs: thiazolidinediones (TZDs) and biguanides.  
 In the present review, the rationale for the use, and data on the 
efficacy for both ISD classes will be detailed. Next, we discuss 
more innovative therapies that, acting through insulin sensitization, 
hold promise for clinical utility in NAFLD and therefore need to be 
validated by testing in the clinical arena. 
SECTION 1. SHOULD WE TREAT INSULIN RESISTANCE 
TO CURE NAFLD? 
A). Pathogenesis of IR 
 IR may be defined in multiple ways but eventually results in 
impaired response to insulin actions. The pathogenesis of IR resides 
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in imbalanced energy homeostasis leading to ectopic lipid accumu-
lation [36]. Physical inactivity, excess caloric intake and altered 
dietary composition are key exogenous factors that promote the 
development of a fatty liver which, in turn, promotes IR [37-43].  
 At the molecular level, hyperglycemia associated with hyperin-
sulinemia promotes the development of hepatic steatosis via up-
regulation of the lipogenic transcription factors including sterol 
regulatory element binding protein-1 (SREBP-1) and peroxisome 
proliferator-activated receptor gamma (PPAR-?), and their down-
stream effector enzymes acetyl-CoA carboxylase (ACC) and fatty 
acid synthase (FAS) [44].  
 In the adipose tissue, impaired insulin-mediated inhibition of 
hormone-sensitive lipase is conducive to increased circulating lev-
els of free fatty acids (FFA) [45], which also closely correlate with 
liver fat content and can further promote hepatic IR [46]. Therefore, 
in humans, peripheral and hepatic IR are closely interrelated. Re-
cent data on the role of the endocrine system and the hypothalamus 
in the development of and worsening of IR have been reviewed 
elsewhere [47]. 
B). The Role of IR in the Development of NAFLD and Cardio-
vascular Disease 
 Epidemiological studies suggest a strong relationship between 
IR and CVD in nondiabetic subjects [48]. IR is associated with 
dyslipidemia and other abnormalities, including oxidative stress, 
endothelial dysfunction and release of proinflammatory cytokines, 
that all contribute to the pathogenesis of CVD [49]  
 Similarly, IR plays a major role in the development and pro-
gression of NAFLD [50-53]. In the EGIR RISC Study, an ongoing 
prospective multicentre project involving a large European Cauca-
sian population of non-diabetic subjects aiming to evaluate the rela-
tionship between IR and cardiovascular risk, fatty liver was associ-
ated with IR, higher Framingham risk scores and increased intima-
media thickness suggesting an increased risk for CHD [54]. In turn, 
hepatic steatosis causes the release of pro-inflammatory cytokines 
such as Interleukin-6 (IL-6) and tumor necrosis factor-? (TNF-?) 
that contribute to fibrosis progression [55-57] and to premature 
arterial aging, hence the concept of an “atherogenic liver” [53].  
 The complex mechanisms that govern the development of stea-
tosis and NASH, including host genetic variability, intestinal dys-
biosis, adipose tissue dysfunction and intrahepatic molecular and 
cellular changes are beyond the scope of this review [58]. However, 
as IR is an independent risk factor for the development of NASH, it 
represents an ideal (but not the only) therapeutic target to prevent 
and treat NAFLD [50,59-61].  
C). The Role of IR in the Development of HCC 
 For HCC occurring in the context of NAFLD/NASH, insulin 
and Insulin-like Growth Factor (IGF) type I receptor family (IIRF) 
are recognized to play a role in promoting tumor growth[62,63] . 
Most cancer types express both the insulin receptor and IGF genes, 
which represent a tyrosine-kinase class of membrane receptors that 
are homologous to oncogenes of the tyrosine-kinase class [64,65]. 
Similarly, there is a relationship between cancer and obesity, and 
cancer risk is closely associated with weight gain, hyperinsulinemia 
and IR [66-69]. Finally, IR leads to the release of multiple pro-
inflammatory, oncogenic cytokines (such as Interleukin-6, tumor 
necrosis factor-?), while hyperinsulinemia stimulates the produc-
tion of IGF-1 that promotes cellular proliferation and a reduction in 
apoptosis [70,71] . 
D). Why Treat IR in NASH? 
 There are several cogent reasons for treating IR associated with 
NASH. First, IR is almost universal in NASH [50], which is associ-
ated with liver-related mortality and cardiovascular disease [1,72]. 
Second, patients with NASH are at a higher risk for developing 
HCC particularly if T2D coexists [73]. Whether and to what extent 
ISDs prevent HCC is a key question in the management of NAFLD. 
Third, IR contributes to the development and progression of both 
NASH and atherosclerosis in subjects with NASH. With regard to 
the latter, it is of interest that metformin reduces vascular stiffness 
in patients with NAFLD, further to, and independent of glycemic 
control [74].  
E). Effects of Current Treatments of IR on NAFLD 
 Lifestyle changes that promote weight loss (diet and exercise) 
and bariatric surgery have proven effective in improving IR and 
reducing the extent of liver steatosis [75,76].  
 A 7-10% weight loss with intensive multidisciplinary lifestyle 
intervention is associated with improving hepatic steatosis, NAFLD 
activity score (NAS) but not fibrosis [77]. Likewise, exercise in-
creases hepatic and extra-hepatic AMPK mediated non-esterified 
fatty acid oxidation, reduces post-prandial hepatic lipogenesis and 
proinflammatory cytokines release, reduces liver steatosis and im-
proves ALT levels [78]. Physical exercise also improves glucose 
metabolism, insulin sensitivity, and atherogenic dyslipidemia with-
out significantly affecting body weight [79]. In contrast, low-
carbohydrate diets significantly reduces waist circumference further 
to improving pancreatic beta-cell function, triglyceride levels and 
insulin sensitivity [80] Weight loss >10% seems to be necessary to 
improve hepatic necroinflammation [81]. 
 Bariatric surgery, indicated to treat severe obesity seems to 
reduce hepatic steatosis, steatohepatitis and fibrosis, and improves 
IR. However this form of therapy is not without complications and 
it is premature to consider foregut bariatric surgery as an estab-
lished option to specifically treat NASH [82]. 
 Recent analysis, however, is inconclusive as to whether the 
reduction in IR is sufficient to improve liver histology [83-85].  
SECTION 2. METFORMIN IN PREVENTION AND 
TREATMENT OF NAFLD  
A). Metabolic Effects of Metformin 
 Metformin is licensed for the treatment of type 2 diabetes melli-
tus at the recommended doses of 500-2500 mg daily. The mecha-
nism of action of metformin, an oral biguanide glucose-lowering 
agent with effects on the mithocondria, has not been fully eluci-
dated, but involves activation of the adenosine monophosphate-
activated protein kinase (AMPK) pathway[86]. Activated AMPK, 
an evolutionarily conserved gauge of intracellular energy depletion, 
switches cell metabolism from an anabolic to a catabolic state, re-
sulting in the inhibition of glucose, lipid and protein synthesis as 
well as cellular growth and increased fatty acid ?-oxidation [87]  
 Glucose metabolism- Metformin decreases intestinal glucose 
absorption and increases insulin mediated glucose uptake in skeletal 
muscle by positive effects on insulin receptor, expression and tyro-
sine-kinase activity [88] . Moreover, metformin seems to increase 
plasma levels of GLP-1 and to induce islet incretin receptor gene 
expression through a PPAR-? mediated mechanism [89] . Met-
formin reduces hepatic gluconeogenesis linking the organic cation 
transporter 1 (OCT1) in hepatocytes, which facilitates the uptake of 
metformin [90] The final result is a reduction in hyperinsulinemia 
[91,9293].  
 Lipoprotein metabolism- AMPK activation by metformin in-
duces the phosphorylation and inactivation of acetyl CoA carboxy-
lase (ACC), an important rate-controlling enzyme for the synthesis 
of malonyl-CoA, which is both a critical precursor for the biosyn-
thesis of fatty acids and a potent inhibitor of mitochondrial fatty 
acid oxidation [94] . Metformin participates in the regulation of 
lipogenic genes expression by down-regulating sterol regulatory 
element-binding protein-1c (SREBP-1c) gene expression [95]. As a 
result of these mechanisms, metformin improves lipoprotein profile 
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by decreasing LDL cholesterol levels and triglycerides, and increas-
ing HDL cholesterol. 
 Others effects- Metformin, by decreasing levels of plasminogen 
activator inhibitor-1 and increasing tissue plasminogen activator 
activity, reduces markers of inflammation and levels of advanced 
glycated end products (AGEs), which are oxidative mediators of 
endothelial dysfunction [96]. Interestingly, metformin also exerts 
anti-hypertensive effects [97]. Moreover, compared to insulin, met-
formin use has recently been associated with a reduced risk of can-
cer, notably HCC [98-101] (Table 1) [97,99,102-119], to which, as 
previously mentioned, diabetic patients appear to be particularly 
vulnerable [14]. Based on these properties, metformin is the “first 
choice” drug for the treatment of type 2 diabetes mellitus, MetS and 
polycystic ovary syndrome (PCOS), all conditions typically associ-
ated with NAFLD [106,120].  
B). Metformin in NAFLD 
 Two meta-analyses of randomized-controlled trials (RCTs) 
have shown that metformin reduces both IR and MetS without im-
proving hepatic histology in NASH [111,112] (Fig. 1) [53]. 
Biochemical Response 
 In a 12-month prospective randomized, placebo-controlled trial 
comparing diet and exercise alone, to diet and exercise plus met-
formin in non-diabetic subjects with IR and NASH, metformin 
(maximum dose 1 gr daily) improved alanine aminotransferase 
(ALT) levels in all groups treated, but there was no correlation with 
histological changes [113,121,122]. In the Diabetes Prevention 
Program (DPP) trial, that compared the effects of a program of diet 
and exercise with treatment with either metformin or placebo in 
overweight or obese adults with elevated fasting glucose or im-
paired glucose tolerance, the improvement in ALT was more sus-
tained if associated with weight reduction. This suggests that the 
effect of metformin on liver tests and hepatic steatosis is mediated 
primarily by weight loss [113,123]. 
Histological Response 
Steatosis 
 Metformin is more effective than diet alone in reducing steato-
sis [124]. Metformin administered in association with antioxidants 
leads to a reduction of hepatic steatosis, without improving neither 
lobular inflammation or hepatocellular ballooning [121].  
 Elevated levels of Fetuin A, a liver-derived glycoprotein that 
critically affects key enzymes in lipid and glucose metabolism, 
impairs insulin signalling and positively correlates with steatosis, 
IR and MetS, [125]. Metformin reduces in vitro the hepatic expres-
sion of Fetuin A suggesting that the metabolic effects of metformin 
are mediated by Fetuin A [126,127]. 
Necroinflammation and Fibrosis 
 Compared to placebo, treatment with metformin leads to im-
proved liver test and reduced IR without any significant differences 
in hepatic histology [128].  
 In one RCT involving nineteen consecutive non-diabetic, but 
insulin resistant subjects with biopsy proven NASH, no improve-
ment in NAFLD activity score (NAS) [129] or fibrosis was ob-
served, whereas steatosis significantly improved [128]. Similarly in 
another report of 20 NASH subjects, no improvement in ballooning 
or lobular inflammation was observed after a 12 month-course of 
metformin supplemented with the antioxidant methyl donor N-
acetyl-cysteine [121]. 
Table 1: Biological effects of metformin in humans. 
Biological Function Parameter/abnormality Action of Metformin Ref 
Insulin-resistance   reduction [102-104] 
Intestinal glucose absorption   reduction [105] 
Glucose-lowering   allow [106] 
Skeletal Muscle gluconeogenesis   increase [107] 
Hepatic gluconeogenesis   reduction [108] 
Hyperlipidemia   reduction of total-C, LDL-C and TG levels [109,110] 
Development of the Metabolic Syndrome  reduction [111] 
Arterial hypertension   reduction [97] 
Improved liver histology in NAFLD  ? [111,112] 
Liver tests  improvement [102,113] 
Cardiovascular risk   reduction [114-116] 
Weight gain   reduction [98,99] 
Development of cancer   reduction [80,100] 
Legend: total-C= Total cholesterol; LDL-C= low-density lipoprotein; TG= triglycerides; ?= null/inconsistent 
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 In their open-label RCT comparing the combination of rosigli-
tazone plus metformin to either drug alone in patients with NASH 
Omer and colleagues found that after 1 year of treatment, steatosis 
and necroinflammation significantly improved with rosiglitazone, 
but not with metformin. The combination of both drugs conferred 
no additional benefit to liver histology and glucose metabolism 
[130]. Thus, although it improves IS, metformin might fail to re-
verse the histological features of NASH. These findings contradict 
the results from an open label, randomized trial conducted in non 
diabetic patients, which reported that metformin at doses of 2 mg 
daily was more effective than either diet or Vitamin E in reducing 
steatosis, necroinflammation and fibrosis [113].  
 Finally, a recent meta-analysis of 78 RCTs confirmed that life-
style interventions that induce weight loss or pioglitazone, but not 
metformin, improves liver histology and cardio-metabolic profile 
[131].  
C). Metformin in Subjects with NASH and Increased CVD Risk 
 A subclinical proinflammatory state is the hallmark of cardio-
vascular risk in NAFLD. Compared to healthy controls, these pa-
tients typically display, significantly higher serum levels of proin-
flammatory cytokines such as C-reactive Protein (CRP), interleu-
kin-6, and TNF-?. Furthermore, hs-CRP levels are higher in sub-
jects with NASH than in individuals with simple steatosis 
[132,133]. Interestingly, Metformin reduces hs-CRP and contrib-
utes to reducing the pro-atherogenic stimulus in subject at higher 
CVD risk [122]. However, no published data specifically clarify 
whether metformin reduces CVD risk in subjects with NAFLD/ 
NASH. 
D). Metformin in HCC and Non-hepatic Cancer 
 Several observational and biological studies suggest a relation-
ship between the use of metformin and a reduction in the incidence 
of various cancer types, including those of the breast, colon, ovary, 
lung and prostate [98,134-138]. Similarly, the use of metformin, 
compared to the use of sulphonylureas or insulin appears to be as-
sociated with a strong and statistically significant reduction in the 
risk of developing HCC, in diabetic patients [100,101]. The mecha-
nisms for this effect are unclear. However, metformin appears to 
reduce carcinogenesis, in part, by inhibiting the synthesis of reac-
tive oxygen species (ROS) production as a consequence of its ef-
fects on mitochondrial function [139], and by regulating the AMP-
activated kinase (AMPK)/mammalian Target of Rapamycin 
(mTORC1) pathway favoring the anti-proliferative effects of 
AMPK [140,141]. Whether such a preventive effect is observed in 
non-diabetic NAFLD patients as well, however, remains to be as-
certained.  
E). Adverse Effects of Metformin 
 Having been used for over 30 years, metformin appears to be 
remarkably safe, with mild gastrointestinal effects alone in a minor-
ity of cases. However, its use is better avoided in case of impaired 
renal function, sepsis and congestive heart failure as in this context 
it is associated with a higher risk of lactic acidosis [84]. 
 In conclusion, metformin alone does not appear to be effective 
for the treatment of NASH, but its use is appropriate in the sub-
group of patients with MetS and increased cardiovascular risk. 
[93,1310,142] (Table 2a) [102,121-123,128,130,143-145].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Mechanisms of action and impact on natural history of NAFLD of glitazones and metformin [53] 
Legend to (Fig. 1): Metformin reduces IR via activation of AMPK, reduces liver steatosis, MetS and cardiovascular risk but does not improve liver histology. 
The PPARs-? (glitazones) reduce IR via activation of multiple pathways, reduce liver steatosis and improve liver histology but are associated with worsening 
cardiovascular disease. IL-6= Interleukin-6; TNF-?= tumor necrosis factor- ?; AMPK= 5'adenosine monophosphate-activated protein kinase; HCC= hepato-
cellular carcinoma; CVD= cardiovascular disease. 
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 Its putative role in preventing HCC in those with type 2 diabe-
tes mellitus adds to the attraction of this agent.  
SECTION 3. THIAZOLIDINEDIONES IN THE PREVEN-
TION AND TREATMENT OF NAFLD  
A). Metabolic Effects of Thiazolidinediones 
 Thiazolidinediones (TZDs or glitazones: pioglitazone and 
rosiglitazone) are licensed for the treatment of type 2 diabetes mel-
litus.. Pioglitazone is administered at the recommended doses of 15-
45 mg daily in a single dose. Rosiglitazone in administered at the 
recommended dose of 4-8 mg daily. TZDs act as agonists of the 
peroxisome-proliferator activated receptor-gamma (PPAR-?), a 
transcription factor that regulates gene expression in liver, adipose, 
vascular endothelium, and muscle tissue. Physiologically, these 
agents promote the differentiation of pre-adipocytes into adipocytes 
and, anatomically, leads to a redistribution of triglycerides from 
liver and muscle (namely from an ectopic site) to adipose tissue (the 
physiological reservoir of fat). Clinically, this leads to improved IS, 
improved glycaemic control, and decreased hepatic steatosis which 
in art occurs via increased concentrations of the insulin sensitizing 
anti-steatotic adipokine adiponectin and consequent activation of 
the AMPK pathway, [146-150]. Recent reports suggest that the use 
of TZDs is associated with a reduced incidence of HCC in type 2 
diabetes mellitus, perhaps via inhibition of promotion and progres-
sion of cancer growth [101,151]. 
 There are unfortunately numerous unwanted side effects and 
potential risks associated with the use of TZDs, including weight 
gain, fluid retention, increased fracture rate, and possibly excess 
cardiovascular events [152,153]. (Fig. 1) [53]. This latter is of par-
ticularly worrisome given that cardiovascular events are a major 
complication in the natural history of NAFLD [154]. A recent meta-
analysis suggests an excess of bladder cancer in type 2 diabetes 
Table 2a: Effect of metformin on liver enzymes and histology in patients with Nonalcoholic Fatty Liver Disease 
Author, year Daily 
Dose 
Liver Enzymes Liver Histology Design Comment Duration Number 
patients 
CVD ou-
tcomes 
Marchesini 
G, 2001 
[102] 
1,5 g improved Not assessed Open label, 
single arm 
Liver volume Reduction  4 months 20 NA 
Bugianesi E, 
2005 [113] 
2 g improved Reduction necroin-
flammation 
Open label, 
RCT 
Associated weight loss 12 months 55 NA 
Uygun A, 
2004  
[143] 
1,7 g improved No significative diffe-
rence in necroinflam-
matory activity 
Open label, 
RCT 
Associated weight loss 6 months 18 NA 
Nobili V, 
2008  
[144] 
1,5 improved No changes in fibrosis Open label, 
RCT 
In children with NAFLD 24 months 10 NA 
de Oliveira 
CP, 2008 
[121] 
1 g improved No improvement in 
inflammation  
Open label, 
single arm 
Benefical effects in Met-
formin + NAC group 
12 months 20 NA 
Idilman R, 
2008 [122] 
1,7 g improved Improved steatosis; not 
significant improve-
ment in fibrosis 
Open label, 
RCT 
Benefical effect on meta-
bolic parameters and hs-CRP 
levels in Metformin group 
12 months 74 NA 
Haukeland 
JW, 2009 
[145] 
2,5-3 improved No improvement Open label, 
RCT 
Reduction in serum lipid and 
glucose 
6 months 48 NA 
Shields VW, 
2009 [128] 
0,5-1 improved No improvement Open label, 
RCT 
Benefical in metabolic ef-
fects 
12 months 19 NA 
Krakoff J, 
2010 [123] 
1,7 improved No improvement  Open label, 
RCT 
Benefical effect if associated 
to weight loss 
3 years 2153 NA 
Omer Z, 
2010  
[130] 
1,7 No improve-
ment 
No improvement Open label, 
RCT 
Benefical effect in Metfor-
min+Rosiglitazone group 
6 months 64 NA 
Legend: CVD= cardiovascular disease; hs-CRP= high-sensitivity C-reactive Protein; NA= not assessed; NAC= N-acetyl-cysteine; RCT= randomized clinical trial. 
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mellitus patients treated with TZDs, in particularly with pioglita-
zone, [155]but these data need to be confirmed.  
B). TZDs in NAFLD 
 There has been significant interest in evaluating TZDs to treat 
NASH. Here we summarize and discuss the results of five RCTs 
and two open label trials using pioglitazone or rosiglitazone (Table 
2b) [156-160]  
Metabolic Response  
 In nondiabetic patients, pioglitazone induces a significant im-
provement in IS as assessed by euglycemic clamps or surrogate 
markers (hyperinsulinemia or homeostasis model assessment 
[HOMA]) [160,161]. A key issue is whether the improvement in 
insulin sensitivity correlates with biochemical and/or histological 
responses. Two studies reported that improved hepatic insulin sen-
sitivity was mirrored by aminotransferase reduction [157], and im-
proved surrogate markers of systemic IR [157,158]. Interestingly, 
the latter improvement was correlated with a reduction in steatosis 
[158]. On closer examination however, metabolic and histological 
improvement do not always coincide [158,160]. For example, al-
though virtually all patients (93%) experiencing a significant reduc-
tion in steatosis also had a reduction in HOMA score, this was also 
the case for a large proportion (59%) of patients with unchanged 
steatosis [158]. Moreover, a subsequent analysis found that even a 
strong reduction in HOMA levels does not predict an improvement 
in necroinflammation or fibrosis. This “dissociation” between the 
improvement of IR and unchanged liver histology has led our group 
to speculate that IR occurs very early in the pathogenesis of 
NAFLD and thus is a factor “necessary but not sufficient” for the 
development of liver disease [85]. 
Biochemical Response  
 Glitazones reduce aminotransferases levels [157,158]. ALT 
levels decline at week 4 and this effect is maintained during treat-
ment. However, treatment longer than one year might not result in 
any further improvements [84,160]. 
Histological Response 
Steatosis  
 Most trials show a reduction in steatosis compared to placebo, 
with a variable individual response ranging from 47% to 65% 
[157,158,160,162]. Only a single trial showed no difference be-
tween groups, perhaps because the patients had minimal steatosis 
(5-25%) at baseline, making differences between groups harder to 
discern [159]. 
Necroinflammation and Fibrosis  
 In published studies, assessment of inflammation is complicated 
by the differing histological scoring systems used. Ballooning im-
proved in 32-54% of patients, significantly more than placebo in 
two RCTs [157,159]. Likewise, in the PIVENS study, the change in 
ballooning was higher with Pioglitazone than placebo [160]. In-
tralobular inflammation improved in all studies [157,159-161] but 
one [158]. Portal inflammation was unchanged or worsened with 
rosiglitazone [162]. 
 Not all studies reported on changes in the NAFLD activity 
score (NAS). In a 6 month study, the score improved in 46% of 
patients treated with pioglitazone versus only 14% of the placebo 
Table 2b: Effect of glitazones on liver enzymes and histology in patients with Nonalcoholic Fatty Liver Disease 
Author, year Daily Dose Liver En-
zymes 
Liver Histology Design Comment Duration Number 
patients 
CVD ou-
tcomes 
Sanyal AJ, 
2004 [156] 
Pioglitazone 30 
mg + Vitamin E 
improved improved RCT Combination therapy 
was superior to Vita-
min E alone in improv-
ing steatosis, necroin-
flammation and 
pericellular fibrosis  
6 months 18 NA 
Belfort, 2006 
[157] 
Pioglitazone 45 
mg + hypocalo-
ric diet 
improved Reduction steatosis and 
necroinflammation 
 RCT The reduction of fibro-
sis do not differ from 
the placebo group. 
6 months 45 No adverse 
effects 
Ratziu V, 2008 
[158] 
Rosiglitazone 8 
mg 
improved reduction steatosis but 
no improvement in 
necroinflammation and 
NAS score versus 
placebo 
 RCT  reduction in markers 
of insulin resistance 
versus placebo 
12 months 63 No differen-
ce versus 
placebo 
Aithal GP, 
2008 [159] 
Pioglitazone 30 
mg + exercise 
and diet 
improved improvement in hepa-
tocellular injury, Mal-
lory- Denk bodies and 
fibrosis 
 RCT increase in weight gain 
versus placebo 
12 months 61 NA 
Sanyal AJ, 
2010 [160] 
Pioglitazone 30 
mg 
improved improvement in steato-
sis and inflammation, 
but no in fibrosis score  
RCT No hepatotoxicity 24 months 80 No differen-
ce versus 
placebo 
Legend: CVD= cardiovascular disease; NA= not assessed; ; RCT= randomized clinical trial. 
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group (p=0.02). This could have been due to a reduction in steatosis 
which is part of the score. In contrast, a 1-year study with rosiglita-
zone failed to demonstrate any significant changes in the NAS 
score [157,,158], whereas a 2-year study with pioglitazone im-
proved the NAS score significantly more than placebo [160] .  
 Even after prolonged treatment with rosiglitazone, fibrosis was 
not altered [84], including when assessed by micromorphometry, a 
more reliable quantitative technique [157,159,161]. 
C). TZDs and HCC and Non-hepatic Cancer 
 Peroxisome-proliferator-activated receptor gamma (PPAR?) 
plays a role in the development of some malignancies, including 
HCC [101,163]. In vitro and in vivo models indicate that the inhibi-
tion of PPAR? is able to inhibit HCC cell proliferation and tumor 
growth by inducing cell cycle arrest and apoptosis via the regula-
tion of a panel of downstream effector molecules [164,165]. PPAR? 
inhibition also induces an inhibitory effect on HCC metastasis 
[166]. Therefore, PPAR? inhibition obtained through administration 
of TZDs could be anti-tumorigenic [167]. (Table 3) [30,100, 
101,165,168-171] 
D). Adverse Effects of TZDs and their use in CVD 
 TZDs are nuclear receptor ligands and have several biological 
effects [172] including unwanted effects such as an increased risk 
of vascular events, precipitation or worsening of congestive heart 
failure, osteoporosis, weight gain, and bladder cancer. Increased 
cardiovascular risk appears to be drug-specific rather than a class 
effect. Further studies are required to evaluate the effectiveness and 
safety of glitazones for the treatment of NAFLD associated with 
either impaired glucose tolerance or overt type 2 diabetes mellitus. 
[174]. 
Rosiglitazone and Pioglitazone Vascular Disease 
 Atherosclerosis is one of the major complication of type 2 dia-
betes mellitus and NASH and the ideal ISD should protect these 
patients from excess cardiovascular risk[174,175]. Concerns remain 
as to whether rosiglitazone increases cardiovascular risks, but it is 
also clear that this drug does not substantially reduce these risks, a 
benefit that would be highly desirable during treatment of NAFLD 
alone or in associated with type 2 diabetes mellitus.  
 Unlike rosiglitazone, pioglitazone has not been associated with 
excess cardiovascular morbility and mortality, as demonstrated by 
the prospective, placebo-controlled PROactive trial [176,177].  
Congestive Heart Failure  
 TZDs have been associated with an increased risk of congestive 
heart failure. The absolute risk, however, is small, amounting to 
0.5% compared to 0.1% for placebo in the DREAM trial of rosigli-
tazone [178], 6% compared to 4% in the PROactive trial [176] of 
pioglitazone, and a doubling of relative risk upon meta-analysis 
[179]. Longer duration of use, age over 50, and obesity are predic-
tive factors for developing congestive heart failure [177]. 
Bone Loss and Fractures 
 Schwartz et al showed that in patients with type 2 diabetes mel-
litus, TZDs use was associated with accelerated bone loss in women 
but not men [180]. Furthermore post-hoc analyses for fractures of 
industry-sponsored trial data confirms that rosiglitazone is associ-
ated with a doubling of the bone fracture rate in women, mostly in 
the arms, hands, and feet. Pioglitazone was similarly associated 
with increased fractures in the distal arm and legs. The mechanism 
is thought to relate to interference of bone formation and turnover 
by TZDs. 
Weight Gain 
 TZDs induce in some but not all patients, a weight gain of ~4 
kg [158,162,176]. This effect is due to expanded peripheral rather 
than visceral adipose tissue and thus does not increase the meta-
bolic and inflammatory abnormalities associated with intra-
abdominal adiposity [181] but rather mirrors redistribution of fat to 
“where it belongs” and is compounded by concurrent fluid retention 
[182,183]. 
 In conclusion, TZDs modestly improve histological parameters 
in NAFLD, but induce weight gain and so further studies are 
needed to demonstrate the long term beneficial effects of these 
drugs for routine use in the prevention and therapy of NAFLD 
[184]. TZDs prevent the development type 2 diabetes mellitus and 
seem to be suitable for use in the subgroup of subjects with im-
paired glucose tolerance and no heart failure [178,185].  
SECTION 4. NAFLD AND INSULIN SENSITIZERS IN 
CHILDHOOD 
 As a result of the overweight and obesity epidemic, NAFLD is 
the most common cause of chronic liver disease and a leading cause 
of liver transplantation in children and teen agers in the United 
States [186,187]. NAFLD in children has a different histological 
spectrum, but as in adults, can evolve to cirrhosis and is associated 
with increased cardiovascular risk [188-173]. 
 As in adults, therapeutic approaches in children are directed to 
reduce IR but, to date, there are no proven therapies that halt pro-
gression or improve prognosis [58,193]. ISDs such as metformin 
and TZDs have been used, although their long-term efficacy and 
safety remain unknown [194]. The TONIC trial was a double blind, 
multicenter randomized trial evaluating NAFLD treatment using 
histologic outcomes. It involved 173 children aged 8 to 17 years 
randomized to receive either metformin, Vitamin E or placebo 
[195]. In the subgroup treated with metformin, improvements in 
ALT and hepatocellular ballooning were detected compared to the 
placebo group, although no significant changes were demonstrated 
in steatosis, inflammation or the NAS score over a 96 week follow-
up. Lifestyle changes aiming to reduce obesity have proven effec-
tive in all age groups and therefore should be adopted [196,197]. 
SECTION 5. INSULIN SENSITIZERS BEYOND MET-
FORMIN AND THIAZOLIDINEDIONES: WHAT'S NEXT? 
 Other ISDs that are potentially useful in human NASH are be-
ing developed or tested. 
 Recent studies have shown a direct and beneficial effect on 
hepatocytes of glucagon-like peptide-1 (GLP-1), a class of drugs 
used for the treatment of type 2 diabetes mellitus. GLP-1, acts by 
activating genes involved in ?-oxidation of fatty acids and insulin-
sensitization [198,199]. In terms of clinical use exenatide, a syn-
thetic version of exendin-4, a hormone initially isolated from the 
saliva of the Gila monster was approved by the FDA for use in the 
US in 2005 as an adjunctive therapy for type 2 diabetes mellitus 
and is available as a subcutaneous injection. This peptide is a GLP-
1 receptor agonist and primarily stimulates the release of insulin 
from pancreatic ?-cells. However, exenatide does not act as a direct 
insulin sensitizer, but rather induces clinically significant weight 
loss, which may eventually lead to an insulin-sensitizing effect. In 
ob/ob mice, exendin-4 significantly reduced blood glucose, im-
proved IS, and reduced hepatic steatosis[200]. GLP-1 proteins have 
a novel direct effect on hepatocyte fat metabolism [201]. 
 An open-label, uncontrolled clinical trial using exenatide to 
assess drug safety in diabetics over a period of ~3.5 years revealed 
that patients had improved AST and insulin sensitivity [202]. In 
addition, those with elevated ALT at baseline (n=116) had signifi-
cant reductions in ALT, while 41% achieved normal levels on 
treatment. Patients with elevated ALT compared to those with nor-
mal ALT levels at baseline tended to lose more weight. However, 
weight change was not correlated with baseline ALT values nor 
were changes in ALT. There is one case report of a 59-year-old 
male with type 2 diabetes mellitus who was treated with exenatide 
and metformin [203]. Following a 44- week course of exenatide, 
this patient displayed normalized ALT, and spectroscopic evidence 
of decreased hepatic steatosis (from 15.8% to 4.3%). 
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Table 3. Insulin sensitizers and prevention of hepatocellular carcinoma 
Author Population studied  Drugs Methodology Results Conclusion  
GLITAZONES      
Chang CH 2012 
[165] 
606,583 diabetic pa-
tients from Taiwan 
followed prospectively 
from 2000 to 2007 
 
Rosiglitazone and 
Pioglitazone 
Prospective case-
control study  
Incidence HCC 
 
rosiglitazone: OR= 
0.73 
(95% CI: 0.65-0.81); 
 
pioglitazone: OR= 
0,83 (95% CI: 0,72-
0,95) 
Decreased liver cancer 
incidence with pioglita-
zone for higher cumula-
tive dose and longer 
duration. 
 
Lai SW, 2012 [101] Taiwan National 
Health Insurance Re-
search Database, 
19,349 newly diag-
nosed T2D patients 
and 77,396 compari-
son subjects without 
DM were identified. 
Metformin and thia-
zolidinediones 
Population-based 
observational study 
from 2000 to 2005. 
Occurrence of HCC: 
HR at 0,49 (95% CI= 
0,37-0,66) in subjects 
taking metformin; at 
0,56 (95% CI= 0,37-
0,84) in subjects tak-
ing thiazolidinediones 
The use of metformin or 
thiazolidinediones may 
reduce the risk of devel-
oping HCC (51% versus 
44% reduction, respec-
tively) in high risk pa-
tients. 
Hassan MM, 2010 
[168] 
140 diabetic patients 
with HCC 
Insulin, metformin, 
sulphonylureas, thia-
zolidinediones 
Hospital-based case 
control study 
The adjusted OR for 
HCC association was 
0,3 (CI= 0,1-0,7; P= 
0,01) in thiazolidin-
ediones users, simi-
larly with metformin 
users (adjusted 
OR=0,3, CI 0,2-0,6; 
P= 0,001)  
 
METFORMIN      
Donadon V, 2010 
[100] 
 
610 HCC patients 
compared with 618 
matched cirrhotic 
patients and 1696 
Controls. 
insulin, sulphonylureas 
and metformin 
Retrospective, hospi-
tal-based, case-control 
study 
metformin compared 
with sulphonylureas: 
OR for HCC of 0.15 
(CI= 0.04–0.50; 
P=0.005);  
 
metformin compared 
with insulin: OR=0.16 
(CI 0.06–0.46; 
P=0.0006) 
In diabetic patients, 
treatment with met-
formin was associated 
with a strong and statis-
tically significant reduc-
tion of the risk of HCC, 
if compared with the use 
of other drugs.  
Chen TM, 2011 
[169] 
53 diabetic patients 
with early-stage HCC 
undergoing RFA 
Metformin versus 
other treatment (sul-
phonylureas, insulin) 
Retrospective analysis 
of a cohort of a single-
hospital database. 
Diabetic patients 
treated with metformin 
had better survival 
outcome compared to 
patients without met-
formin treatment: 
adjusted HR 0,24 
(95% CI: 0,07-0,80, 
P=0,020) 
No difference in mortal-
ity rate between patients 
taking metformin and 
nondiabetic patients. 
Sulphonylureas and 
insulin treatment did not 
achieve significant con-
clusions. 
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(Table 3) Contd…. 
 
Author Population studied  Drugs Methodology Results Conclusion  
Nkontchou G, 2011 
[170] 
100 consecutive dia-
betic patients with 
HCV cirrhosis in-
cluded in 
a screening program 
for HCC. 
Metformin Observational prospec-
tive cohort (1988-
2007) at 
a university hospital 
referral center. 
Occurrence of HCC: 
HR at 0,19 (95% CI= 
0,04-0,79, P= 0,049) 
in group treated with 
metformin. 
Treatment with met-
formin reduces incidence 
of HCC and liver-related 
mortality in patients with 
diabetes and HCV. 
Lai SW, 2012 [101] Taiwan National 
Health Insurance Re-
search Database, 
19,349 newly diag-
nosed T2D patients 
and 77,396 compari-
son subjects without 
DM were identified. 
Metformin and thia-
zolidinediones 
Population-based 
observational study 
from 2000 to 2005.. 
Occurrence of HCC: 
HR at 0,49 (95% CI= 
0,37-0,66) in subjects 
taking metformin; at 
0,56 (95% CI= 0,37-
0,84) in subjects tak-
ing thiazolidinediones 
The use of metformin or 
thiazolidinediones may 
reduce the risk of devel-
oping HCC (51% versus 
44% reduction, respec-
tively) in high risk pa-
tients. 
Chen HP, 2012 [171] 97430 HCC patients, 
194860 controls  
metformin Population-based case-
control study 
In diabetics, adjusted 
HCC OR= 0,93 (95% 
CI 0,91-0,94, 
p<0,0001) 
In diabetic patients, each 
incremental year in-
crease in metformin use 
resulted in 7% reduction 
in the risk of HCC. 
Wang P, 2012 [30] More than 2 000 000 
partecipant with diabe-
tes were included in 
meta-analysis 
metformin Meta analysis of 17 
case-control studies 
and 32 cohort studies 
Pooled risk of HCC 
estimates were 0,31 
(95% CI= 0,19-0,49) 
for patients receiving 
metformin, and 4,0% 
(95% CI= 1,94-8,24) 
for patients receiving 
sulphonylureas or 
insulin treatment.  
Metformin reduces inci-
dence of HCC in diabetic 
patients, in comparison 
to other antidiabetic 
drugs. 
 
 The long-acting glucagon-like peptide liraglutide also im-
proves insulin sensitivity and reduces lipid accumulation in liver 
through multiple and incompletely understood mechanisms [204, 
205].  
 Liraglutide, has 97% amino acid sequence identity to native 
human GLP-1 and an acyl side-chain attachment, which makes it 
bind to albumin. These small structural differences prolong the 
half-life of GLP-1 to 13 hours, making it possible to administer 
daily. Several studies showed that liraglutide was well tolerated, 
improved glycaemic control with a low risk of hypoglycemia, im-
proved beta-cell function, and was associated with weight reduc-
tion. The receptors of GLP-1 analogues also exist in human hepato-
cytes and administration of GLP-1 analogues are reported to di-
rectly reduce liver steatosis and fibrosis in vivo [201,206]. More 
studies are underway to ascertain its effect in NAFLD/NASH[207]. 
 Similarly, the dipeptidyl peptidase-IV inhibitor (DPP-IV) sita-
gliptin improves postprandial insulin secretion, reduces excess glu-
cagon secretion, promote saxiety, ameliorates liver tests in T2D and 
affects liver fibrogenesis either via increasing GLP-1 activity and/or 
anti-inflammatory activities in liver [208-211]. In a recent open-
label, single-arm observational pilot study, treatment with sita-
gliptin (100 mg once a day per 12 months) ameliorated liver en-
zymes and hepatocyte ballooning in NASH patients with type 2 
diabetes mellitus [212].  
 Other PPAR agonists have been shown to have insulin-
sensitizing effects and thus are potentially indicated for use in 
NAFLD. These include the PPAR-? agonist GW501516 which has  
 
been examined in a mouse model of NASH [213]. GW501516 re-
duced hepatic triglyceride, hepatic fat droplets, inflammatory cells, 
and decreased the expression of pro-inflammatory markers. Like-
wise, PPAR-? agonist treatment in an ethanol-mediated hepatic 
injury and steatosis rat model attenuated the severity of adverse 
effects from ethanol on hepatic repair by restoring insulin respon-
siveness [214]. Collectively, these findings suggest that PPAR-? is 
a potential therapeutic target for IR and hepatic steatosis [215,216]. 
 Finally, there was initial promise with the cannabinoid type I 
(CB1) receptor blockers in improving hepatic steatosis and pro-
moting weight loss in NAFLD. The endocannabinoid system is 
involved in the regulation of food uptake, body weight, and insulin 
sensitivity. Obesity leads to up-regulation of the CB1 receptors, 
which leads to hepatic lipogenesis, fatty acid synthesis in adipo-
cytes, and decreased adiponectin levels [217]. In two large, pla-
cebo-controlled clinical trials using the CB1 antagonist rimona-
bant to study weight loss, metabolic improvements were remark-
able with notable improvements in insulin sensitivity [218,219]. 
This was largely thought to be due to weight loss, but the metabolic 
effects appear to exceed what is directly related to weight loss 
alone, suggesting a direct action in improving insulin sensitivity. 
While there were several CB1 antagonists in development (Ri-
monabant (SR141716), taranabant, and otenabant), enthusiasm for 
these agents has waned after Rimonabant, was withdrawn from the 
market in the European Union due to adverse psychiatric effects, 
mostly severe depression, and suicidal behavior [220]. Current 
research is devoted to developing peripherally selective CBI an-
tagonists devoid of the psychiatric adverse effects.  
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 Impaired regulation of bile acid metabolism may contribute to 
the development of NAFLD. Ursodeoxycholic acid (UDCA) im-
proves hepatic metabolism and insulin sensitivity by multiple ef-
fects including the regulation of de novo lipogenesis, stimulation of 
glucagon-like peptide-1 secretion in the small intestine, and im-
proved energy homeostasis in brown adipose issue and skeletal 
muscle [221,222]. However clinical trials of these agents in NASH 
have provided negative results and bile acids are not recommended 
[223]. 
 Statins have immunomodulatory and anti-inflammatory ac-
tions, useful in the treatment of both CVD and NASH [224-229]. 
Individual statins such as rosuvastatin have been shown to exert a 
beneficial effect in improving insulin sensitivity in animal models 
of NAFLD [230]. However there are no sufficiently powered stud-
ies to demonstrate a beneficial effect of these agents on liver histol-
ogy in human NAFLD/NASH. 
 Oxidative stress induced by lipid peroxidation and the produc-
tion of reactive oxygen species (ROS) are key-mechanisms for the 
development of NASH and cardiovascular disease. Antioxidant 
agents (including Vitamin E, betaine and N-acetyl-cysteine) may 
therefore be effective in treating NASH and improve liver enzymes 
and histology as recently demonstrated by the PIVENS trial [160]. 
However, the data need to be replicated in well-designed random-
ized controlled trials that are adequately powered and of a sufficient 
duration to determine clear efficacy [160,231,232].  
 Adiponectin is an adipocytokine with pleiotropic effects acting 
principally through AMPK pathway activation [233-235] including 
a reduction in the formation of vascular plaques, improving insulin 
sensitivity and glucose control, and anti-inflammatory and anti-
fibrogenic actions in the liver which results in protective effects 
against HCC [236-240]. 
 Adiponectin is a hepatic insulin sensitizer and inhibitor of tu-
mor necrosis factor, and in NAFLD, low adiponectin levels are 
associated with reduced steatosis and inflammation [241-243]. 
Conversely, elevated serum concentrations of adiponectin are asso-
ciated with protective effects against hepatic steatosis [60, 244, 
245]. Thus, adiponectin agonists may be beneficial for the treatment 
of NAFLD in future.  
 Estrogens - Interestingly, estrogens may be considered as ISDs 
[246-248]. Estrogen receptors (ER) are expressed in many tissues 
including the liver and white adipose tissue, and estrogens act via 
nuclear and extranuclear pathways [249,250]. Estrogens stimulates 
leptin synthesis and secretion via ER-dependent transcriptional 
mechanisms, leading to metabolic regulation [251]. The finding that 
human NAFLD demonstrates sexual dimorphism in its manifesta-
tions [252-254], that treatment with the antiestrogen tamoxifen 
[255] and naturally occurring hyperandrogenism in PCOS [256] are 
associated with NASH and that hormonal replacement therapy is 
associated with antifibrotic activity in women with chronic hepatitis 
C [257] and that estrogens exert hepatoprotective effects in vitro 
Table 4. Comparison of the Effectiveness of the Various Insulin Sensitizers in NASH 
Drug NAFLD Complications of NAFLD REFERENCES 
 Liver 
enzymes 
Liver stea-
tosis 
Liver fi-
brosis 
HCC non-HCC 
Cancer 
CVD MetS  
Metformin   reduction  reduction  indifferent  reduction reduction reduction reduction [62,102,102,112,115,116,134,135,137,262] 
Glitazones   reduction reduction reduction reduction reduction worsening  reduction [101,115,263] 
DPP-IV in-
hibitors 
 reduction   reduction ? ? ?  reduction  reduction [210,211,264,265] 
GLP-1 ago-
nists 
 reduction reduction reduction/? ? ?  reduction reduction [198-200,202,204,266-267] 
Lipid-
lowering 
drugs 
 reduction  reduction ?  reduction reduction  reduction reduction [227,270-274] 
Antioxidants  reduction reduction ? ? ? worsening 
or no 
effect 
 ? [160,231,232,275-277] 
UDCA   reduction reduction ? ?/ worse-
ning 
?/ worsening  benefical benefical [221-223,278,279] 
Angiotensin 
receptor 
blockers  
(AT-1)  
 reduction reduction  reduction ?/ reduc-
tion 
?/ reduction reduction reduction [280-283] 
Legend: NAFLD= nonalcoholic fatty liver disease; HCC= hepatocellular carcinoma; CVD= cardiovascular disease; MetS= Metabolic Syndrome; DPP-IV= dipeptidyl peptidase IV; 
GLP-1= glucagon-like peptide 1; UDCA= Ursodeoxycholic acid; Antioxydant= Vitamin E, betaine, N-acetyl-cysteine; Lipid-lowering drugs= statins, fibrates, niacin, ezetimibe, n-3 
polyunsaturated fatty acids (PUFAs). 
 “?”= undetermined effect.  
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[258], all suggest that estrogens may have a role in the management 
of NAFLD. However, no clinical data are available in this regard.  
CONCLUSIONS 
 Suggestions for the use of the most relevant ISDs in clinical 
practice have been detailed in conclusions to Section 2 and Section 
3. Certain agents such as metformin and thiazolidinediones might 
be appropriate for early stage disease (i.e. pure steatosis). In cases 
of NASH/cirrhosis, particularly in those with decompensated liver 
disease, metformin should be used with caution.  The strong patho-
genic association of IR with NAFLD justifies further consideration 
of the use of ISDs. Available data suggest that the pathogenesis of 
liver injury in this disease is multi factorial [259] and clinical trials 
of a combined therapeutic approach including various ISDs classes 
needs to be considered. [260,261].  
 Finally, fully innovative research avenues are disclosed by the 
finding that other novel “non-classic” insulin sensitizers may be of 
potential utility in the prevention and treatment of NAFLD and its 
metabolic, hepatic and extrahepatic vascular and oncologic compli-
cations (Table 4). [62,101,102,111,115,116,134,135,137,160,198-
200,202,204,210,211,221-223,227,231,232,262-283] 
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ABBREVIATIONS 
ALT =  Alanine aminotransferase 
CHD =  Coronary heart disease 
CVD =  Cardiovascular disease 
DPP-IV =  Dipeptidyl peptidase-IV inhibitors 
GLP-1 =  Glucagon-like peptide-1 
HCC =  Hepatocellular carcinoma 
IR =  Insulin Resistance 
ISDs  =  Insulin-sensitizer drugs 
MetS =  Metabolic Syndrome 
NAFLD =  Nonalcoholic fatty liver disease 
NAS =  NAFLD score  
NASH =  Nonalcoholic steatohepatitis 
PCOS =  Polycystic ovary syndrome 
T2D =  Type 2 diabetes mellitus 
TZDs =  Thiazolidinediones 
TGs =  Triglycerides 
UDCA =  Ursodeoxycholic acid 
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